There is a high prevalence of hypertension and hypertension-related vascular disease in humans. Studies show that the expression of stem cell factor (SCF)/c-kit signalling proteins is relatively high during blood vessel repair. The aim of this study was to investigate the relationship between blood pressure (BP) and the expression of SCF/c-kit in peripheral blood. We carried out a cross-sectional analysis of 141 subjects in the health examination centre of our hospital. Information including waist circumference, BP, plasma glucose and serum lipids for each subject was collected. Endothelin-1 (ET-1) and tumour necrosis factor-a (TNF-a) levels in peripheral blood were determined by radio-immunity assay. Expression levels of SCF and its receptor, c-kit, in peripheral blood were measured by enzyme-linked immunosorbent assay (ELISA). We found a positive correlation between plasma SCF/c-kit levels and BP in these patients (SCF: hypertension 907.1±52.3 vs prehypertension 834.6 ± 47.6 vs normal control 768.8 ± 44.1 ng l À1
Introduction
A large body of evidence indicates that vascular endothelial dysfunction is the most critical phase in the development of hypertension. 1 The early stage of hypertension is characterized by small artery dysfunction and spasticity. Arterial remodelling, degeneration, thickening, luminal narrowing and reduction of diastolic function characterize the advanced stage of hypertension. Once the endothelium is activated, stem cells, such as mesenchymal stem cells, endothelial progenitor cells and peripheral blood stem cells, are mobilized to promote vascular repair or angiogenesis. 2 Massa et al. 3 showed that CD34 þ peripheral blood stem cells and endothelial progenitor cells are significantly elevated in patients with acute myocardial infarction and remain elevated for 2 months after the event. Another report showed that an alteration in the pro-angiogenic function of progenitor cells may contribute to hypertension-induced impairment of post-ischaemic revascularization. 4 Stem cell factor (SCF)/c-kit is a new type of multifunctional cytokine that has an important role in the animation, proliferation and differentiation of adult stem cells. 5 In a previous study, we found that the level of c-kit expression in peripheral blood mononuclear cells is significantly elevated in patients with acute myocardial infarction, and the amount of elevation is directly proportional to the severity of the myocardial infarction. 6 However, the relationship between SCF/c-kit and blood pressure (BP) levels is still unclear. The present study explored the relationship between SCF/c-kit and BP by investigating whether SCF/c-kit levels in the peripheral blood are associated with BP and other markers of hypertension.
Methods

Subjects
A total of 141 subjects between the ages of 32 and 72 years were selected for this study. Inclusion criteria were as follows: no previous diagnosis of infections, cancers, liver, kidney or chronic wasting diseases; no previous treatment with anti-hypertensive or anti-diabetic drugs or any other drug known to affect glucose and lipid metabolism; absence of diabetes or severe obesity; and no history of coronary heart disease, heart failure, stroke or important concomitant disease. Subjects were studied within 3 months of their first visit. Using the Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC-7), we divided the subjects into three groups according to their BP levels: normotensive, prehypertensive and hypertensive. All subjects gave informed consent to participate in the study.
We obtained the following from each subject: (1) gender, age, education level, smoking and drinking history; (2) past history of hypertension, diabetes, high cholesterol, coronary heart disease, myocardial infarction, stroke and other cardiovascular disease, history of drug-related diseases and asked the situation; (3) family history of hypertension, diabetes and coronary heart disease; (4) measurement of body weight, height, waist circumference and hip circumference; and (5) quantitation of plasma glucose, creatinine, uric acid, urea nitrogen and serum lipid using an automatic biochemical analyzer. Body mass index was calculated as an index for obesity.
Measurement of BP
Systolic blood pressure (SBP) and diastolic blood pressure (DBP) were measured by two trained staff members using a mercury sphygmomanometer (0008-1000 hours). Three sets of BP measurements were obtained, and the reported SBP and DBP pressures (mm Hg) were the average of these three measurements. Using the SBP and DBP measurements, three levels of BP status were established by the investigator according to the JNC-7 criteria: normotensive (SBP o120 mm Hg, DBP o80 mm Hg), pre-hypertensive (SBP 120-139 mm Hg, DBP 80-89 mm Hg), hypertensive (SBP X140 mm Hg, DBP X90 mm Hg). If a subject's SBP and DBP put him or her in two separate categories, the higher level determined the subject's BP status. Mean BP was calculated as DBP plus one-third of the pulse pressure.
Assays for SCF, c-kit, endothelin-1 (ET-1) and tumour necrosis factor-a (TNF-a) Fasting blood samples (4 ml) were collected in the early morning after 30 min of rest and immediately transferred into two glass tubes. One tube, containing disodium EDTA and aprotinin, was used for the measurement of plasma ET-1 and TNF-a. The other tube contained heparin and was used for the SCF and c-kit measurements. All plasma samples were frozen at À20 o C, and plasma ET-1 and TNF-a levels were measured within 4 weeks of collection using a commercial specific immunoradiometric assay (Biotechnology Institute of Beijing, Beijing, China). SCF and c-kit were measured by enzyme-linked immunosorbent assay (ELISA) kits (R&D Systems, Minneapolis, MN, USA).
Statistical analysis
Results are expressed as mean ± s.d. Parameters among the three groups were compared by oneway analysis of variance. The relationship between cardiovascular risk factors and BP were analyzed using simple linear regression and multiple linear regressions. All statistical analyses were carried out on the Stata7.0 (StataCorp, College Station, TX, USA) and Excel software (Microsoft, Redmond, WA, USA). Statistical significance was set at Po0.05. 
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Results Table 1 shows the clinical characteristics, BP, serum creatinine, plasma glucose, plasma uric acid, plasma urea nitrogen and serum lipid levels of the normotensive, pre-hypertensive and hypertensive groups. There were no differences in smoking (data not shown), heart rate (data not shown) and waist-hip ratio (data not shown) among the three groups. Interestingly, we found that the body mass index, urea nitrogen, creatinine, uric acid and plasma glucose increased significantly with BP, whereas cholesterol (total, high density lipoprotein and low density lipoprotein) and triglycerides were not different among the groups.
Baseline characteristics
Serum levels of SCF, c-kit, TNF-a and ET-1 Table 2 shows the serum levels of SCF, c-kit, TNF-a and ET-1 among the three groups. The levels of TNF-a and ET-1 increased with increasing BP. Moreover, we found that the serum level of SCF was significantly increased in the pre-hypertensive subjects compared with the normotensive group (834.6 ± 47.6 vs 768.8 ± 44.1 ng l À1 , Po0.01). The hypertensive patients had significantly elevated serum SCF compared with both the normotensive group (907.1 ± 52.3 vs 768.8 ± 44.1 ng l À1 , Po0.01) and the pre-hypertensive group (907.1±52.3 vs 834.6±47.6 ng l À1 , Po0.01). We observed the same pattern in the three groups for the serum levels of c-kit.
The linear regression analysis between SCF/c-kit, TNF-a and ET-1 Figure 1 shows the relationships between plasma SCF/c-kit levels and SBP, DBP, TNF-a and ET-1. Plasma SCF/c-kit levels were positively correlated with SBP, DBP, TNF-a and ET-1.
Multiple linear regression analysis of the relationships between SCF/c-kit, TNF-a, ET-1 and BP levels For multiple linear regression using SBP as the dependant variable and SCF, c-kit, TNF-a and ET-1 as independent variables, R2 ¼ 0.65 and SCF .05) entered the equation. They were correlated with DBP. Multiple linear regression analysis showed that SCF, c-kit and ET-1 were independent risk factors for SBP, whereas SCF, c-kit, ET-1 and TNF-a were independent risk factors for DBP.
Discussion
In this study, we showed that the serum levels of SCF and c-kit increase with BP levels. Serum levels of SCF and c-kit were elevated in pre-hypertensive patients compared with normotensive patients, and serum levels of SCF and c-kit in hypertensive patients were significantly higher than in the two groups with lower BPs. Furthermore, our results indicate that serum SCF and serum c-kit are positively correlated with ET-1 and TNF-a levels.
Identified as a mast-cell growth factor, 7 SCF is found in either a soluble or transmembrane form and may contribute to cell activation. 8 Soluble SCF can activate mast cells, leading to the expression of cytokines, such as histamine, TNF-a, interleukin-4 and interleukin-10.
9,10 Transmembrane SCF has a role in the exacerbation of mast-cell activation (histamine release) and eotaxin production, which could lead to increased eosinophil accumulation and tissue pathology. 11 The receptor of SCF, c-kit, was originally identified as a human proto-oncogene and encodes a 145 kDa membrane-spanning receptor belonging to a subclass of receptor tyrosine kinases.
12 C-kit is highly expressed in haematopoietic stem cells and binds to its endogenous ligand SCF, which maps to the steel locus. 13 The SCF/c-kit pathway is involved in many biological processes including the differentiation and proliferation of haematopoietic cells (e.g., mast cells and erythroblasts), germ cells and melanocytes.
14,15 and the development of cardio-cerebral vascular diseases. SCF is a hypoxia-induced nerve regeneration factor, stimulating nerve regeneration in vivo and in vitro. 16 The SCF/c-kit pathway is also involved in the migration of neural stem/progenitor cell to sites of both brain and myocardium injury. The SCF/c-kit pathway induces progenitor cell recruitment to ischaemic areas of the brain, 17 while also being involved in the ischaemia/reperfusion cascade in myocardium. SCF was recently found to improve cardiac function after myocardial infarction by modulating the mobilization of stem cells from the bone marrow. 18 Kuhlmann et al. 19 reported that SCF increased cardiomyocyte diameter, arteriogenesis and expression of connexin-43 in the border zone of the infarction. According to Tian et al., Relationship between stem cell factor H-L Zhong et al SCF can improve cardiac function after myocardial infarction in mice. In addition to the brain and the myocardium, SCF/c-kit has a role in blood-vessel repair. After bubble injury occurred in the carotid artery of mice, SCF/c-kit was released from the combined membrane of vascular smooth muscle cell through matrix metalloproteinases-9, and c-kit expression was significantly increased. 21 Wang et al.
22
confirmed that SCF/c-kit has an important role in the defence of vascular smooth muscle cells apoptosis and endomembrane hyperplasia. Our findings showed a linear and independent relationship between BP and SCF/c-kit levels. We hypothesized that hypertension is related to endothelial dysfunction, triggering SCF/c-kit activation. 23 Endothelial function is greatly influenced by cytokines, such as TNF-a, 24 ET-1, 25 angiopoietin-1, 26 leptin, 27 visfatin 28 and adiponectin. 29 Endothelial activation is characterized by enhanced production of cytokines and increased expression of adhesion molecules leading to an increased leucocyte adhesion and transmigration into the intima of the vessel wall. 30 Increasing BP leads to a gradual increase in endothelial injury. To strengthen the recovery of blood-vessel endothelium, stem cells are increasingly mobilized, consistent with the fact that the level of endothelial progenitor cells in circulation is an independent risk factor for the prognosis of ischemic damage. 31 Endothelial dysfunction leads to the development of hypertension 32 and disequilibrium of ET-1/nitric oxide activity. 33 We believe that SCF/kit is also a cytokine that affects endothelial This study also showed a strong linear relation between SCF/c-kit and inflammatory factors. The association between hypertension and a pro-inflammatory status may help explain this phenomenon. Important regulators of BP, such as the reninangiotensin system, depend on pro-inflammatory cytokines produced by the interaction of interleukin-6 and TNF-a interaction. Thus, pro-inflammatory factors may increase the expression of SCF/c-kit levels. Another explanation for the observed trend may include the close relationship between hypertension and vascular endothelial dysfunction. The endothelial system has an important role in the regulation of BP, 34 and hypertension is one of the initiating agents of endothelial injury. 23 Endothelial function has evolved as a surrogate for the development and progression of hypertension. The irreversible damage of arterial wall structure and function has an important role in the patho-physiological process of hypertension. Hypertension progression would be delayed if the damage of vascular remodelling could be reversed. The SCF/c-kit system may be involved in repairing of damaged blood vessels. However, future prospective clinical investigations are required to further explore this possible pathway.
In conclusion, our results show that the serum levels of SCF and c-kit increase in pre-hypertension and are especially increased in hypertensive patients. SCF/c-kit levels are also positively correlated with serum levels of ET-1 and TNF-a. These findings provide important insight into the genesis of hypertension, providing possible avenues of new treatments for this disease.
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